{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000097","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.966264+00:00","generated_at":"2026-05-31T11:48:03.144381+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income","bullets":["Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).","GAAP operating loss narrowed to $107M from $319M; non-GAAP operating income of $48M (positive inflection point).","Proposes redomicile from Cayman Islands to Switzerland; opens $800M biologics facility in New Jersey.","Pipeline: advancing sonrotoclax (BCL2i) and BGB-16673 (BTK degrader); over 15 solid tumor molecules in development.","BRUKINSA leads BTKi class in U.S. new patient starts across all approved indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000097","json":"https://secwatch.observer/filing/0001651308-24-000097.json","markdown":"https://secwatch.observer/filing/0001651308-24-000097.md","text":"https://secwatch.observer/filing/0001651308-24-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000097/0001651308-24-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000097/bgne-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:48:03.144381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}